Peptide Receptor Radionuclide Therapy (PRRT) has been around for a while and doctors are learning all the time about the most likely candidates. Selection of candidates and predictions on who will benefit most are still not an exact science (….and possibly never will be). Neuroendocrine Neoplasms are a heterogenous grouping of cancers, and heterogeneity also includes (but is not limited to) age, stage, gender, functional/non-functional, and pre-existing condition constraints. All of this complicates the task of therapeutic decision-making and sequencing.
The attached cohort study aims to bound the issue and describe a method of allocating a Clinical Score (CS) to assist doctors and patients in their decision-making. According to the lead author, the CS is the initial prognostic score to help NET patients anticipate expected benefit from PRRT and is ready for use in the clinic (although the actual document does suggest it requires prospective confirmation from ongoing clinical trials).
This is progress.
This cohort study has found the Clinical Score (CS) to be the first validated clinical metric, to our knowledge, which can estimate the anticipated benefit from 177Lu-dotatate for individual patients. Our study findings suggest that using 177Lu-dotatate when patients are less pretreated and possess a lower degree of metastatic involvement may optimize treatment outcomes; this notion, however, requires prospective confirmation from ongoing clinical trials. Click on the heading below to read.
External Validation of a Clinical Score for Patients With Neuroendocrine Tumors Under Consideration for Peptide Receptor Radionuclide Therapy | Oncology | JAMA Network Open | JAMA Network (click here)
Click on the photo to read:
Top 10 Posts & Pages in the last 48 hours (auto updates)
Thanks for reading.
Sign up for my newsletters – Click Here
Please Share this post for Neuroendocrine Cancer awareness and to help another patient
- European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for Digestive Neuroendocrine Carcinoma
- Neuroendocrine Cancer – Clinical Esoterica
- Neuroendocrine Cancer – The F Words
- Laughter is the best medicine
- European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for gastric neuroendocrine tumours (NETs) G1–G3